Highly efficient CRISPR/Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa
Open Access
- 17 January 2024
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (4) , e10640
Abstract
Gene therapy based on the CRISPR/Cas9 system has emerged as a promising strategy for treating the monogenic fragile skin disorder recessive dystrophic epidermolysis bullosa (RDEB). With this approach problematic wounds could be grafted with gene edited, patient‐specific skin equivalents. Precise gene editing using homology‐directed repair (HDR) is the ultimate goal, however low efficiencies have hindered progress. Reframing strategies based on highly efficient non‐homologous end joining (NHEJ) repair aimed at excising dispensable, mutation‐harboring exons offer a promising alternative approach for restoring the COL7A1 open reading frame. To this end, we employed an exon skipping strategy using dual single guide RNA (sgRNA)/Cas9 ribonucleoproteins (RNPs) targeted at three novel COL7A1 exons (31, 68, and 109) containing pathogenic heterozygous mutations, and achieved exon deletion rates of up to 95%. Deletion of exon 31 in both primary human RDEB keratinocytes and fibroblasts resulted in the restoration of type VII collagen (C7), leading to increased cellular adhesion in vitro and accurate C7 deposition at the dermal‐epidermal junction in a 3D skin model. Taken together, we extend the list of COL7A1 exons amenable to therapeutic deletion. As an incidental finding, we find that long‐read Nanopore sequencing detected large on‐target structural variants comprised of deletions up to >5 kb at a frequency of ~10%. Although this frequency may be acceptable given the high rates of intended editing outcomes, our data demonstrate that standard short‐read sequencing may underestimate the full range of unexpected Cas9‐mediated editing events.Keywords
Funding Information
- Auckland Medical Research Foundation (1120018)
- Maurice and Phyllis Paykel Trust (203136)
- Cure Kids (3591)
- Faculty of Science, Prince of Songkla University (3717415)
This publication has 34 references indexed in Scilit:
- Allogeneic fibroblast cell therapy in the treatment of recessive dystrophic epidermolysis bullosaWound Medicine, 2018
- Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cellsJournal of Experimental Medicine, 2018
- Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse modelProceedings of the National Academy of Sciences, 2017
- CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosanpj Regenerative Medicine, 2016
- Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB ModelJournal of Investigative Dermatology, 2016
- Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapyMolecular Therapy, 2016
- Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral VectorJournal of Investigative Dermatology, 2016
- Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis BullosaMolecular Therapy Nucleic Acids, 2016
- Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteinsGenome Research, 2014
- Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosaNature Genetics, 2002